ACADIA Announces Presentation Of Data On Pimavanserin Co-Therapy At The 14th Biennial Winter Workshop On On Schizophrenia And Bipolar Disorders

ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that Murray Rosenthal, D.O.

More: continued here

Filed under: Bipolar on February 7th, 2008